ALDERLEY PARK, June 22 -- PRNewswire/ AsiaNet
A Virtual Press Briefing (webcast) Today
New data from the large-scale BOLDER study examine the effect of Seroquel(TM) in the treatment of bipolar depression and its associated anxiety symptoms. The data from this study will be presented at the 24th Collegium Internationale Neuro Psychopharmacologicum (CINP) Meeting in Paris, France, June 20 - 24, 2004.
AstraZeneca will be holding a virtual press briefing (webcast) today where the key results from this highly significant trial will be presented.
This will be your opportunity to....
- Hear from leading psychiatry expert, Dr Eduard Vieta (Spain), on the symptoms associated with this distressing condition and the its current management.
- Hear from the BOLDER Lead Study Investigator, Dr Joseph Calabrese (USA), about the results of the BOLDER study and the implications on current practice and the benefits to patients.
- Hear from a patient talking about their personal experiences of living with bipolar disorder and understand the real significance of these results to sufferers.
How and When?
To view and listen to the presentations, you can access the webcast from
13.30hrs (CET), Tuesday 22 June 2004
via www.AstraZenecaPressOffice.com where a link will
take you to the webcast.
Press materials will also be available on
www.AstraZenecaPressOffice.com
If you have not already done so, you will need to register on www.AstraZenecaPressOffice.com prior to viewing the webcast. The registration is simple, quick, and immediately following registration you will be provided with a password for future access. You will need to use this password when accessing the webcast and presentations on the website.
'Seroquel' is a trade mark of the AstraZeneca group of companies. This webcast is not intended for US or French media. Seroquel is not currently licensed for the treatment of bipolar depression.
If you have any questions regarding access to the webcast please do not hesitate to contact Lisa O'Sullivan or Drew Owen on +44-(0)207-471-1500 or email: lisa.o'[email protected] or [email protected] who will be pleased to assist you. Telephone Interviews - Should you wish to interview the presenters, other lead investigators or AstraZeneca spokespeople please contact Lisa O'Sullivan on +44-(0)207-471-1500 or email: lisa.o'[email protected]
SOURCE: AstraZeneca
--Distributed by AsiaNet (www.asianetnews.net)--